Brazil’s Emerging Biologics Sector: Domestic Drugmakers Poised to Challenge Global Pharma Dominance
The expiration of the semaglutide patent in Brazil is catalyzing a shift in the pharmaceutical landscape, enabling local manufacturers to produce complex biologic drugs and compete with multinational companies. This development signals a strategic advance for Brazil’s pharmaceutical industry, with implications for drug pricing, healthcare access, and industrial capacity.